"Multiple sclerosis, interferon beta and clinical
thyroid dysfunction"
Kreisler A, de Seze J, Stojkovic T,
Delisse B, Combelles M, Verier A, Hautecoeur P, Vermersch P; Groupe
septentrional d'etude et de recherche sur la Sclerose en Plaques
(G-SEP).
Department of Neurology, Lille University Hospital, France.
The objective of this study was to
investigate frequency and presentation of clinical thyroid
dysfunction in patients treated with interferon beta (IFN-beta).
We have collected the cases of clinical
thyroid dysfunction in 700 consecutive patients receiving IFN-beta
for multiple sclerosis (MS). Five patients (four women, one man)
treated with IFN-beta1b developed hyperthyroidism. Three of them
have secondary progressive MS, and two have relapsing-remitting MS.
It was necessary to stop IFN-beta in
three cases; these patients still require carbimazole after several
months. In the two other cases, hyperthyroidism disappeared
spontaneously. Two patients (one man and one woman) treated with
IFN-beta1a developed hypothyroidism. One of them required l-thyroxine.
Lastly, an increased thyroid volume
without modification of thyroid hormones plasma levels was
discovered in a patient receiving IFN-beta1a. Among patients treated
with IFN-beta, clinical thyroid dysfunction is much rarer than
laboratory thyroid dysfunction. However, this side-effect is
sometimes severe.
Acta Neurol Scand 2003 Feb;107(2):154-7
PMID: 12580868 [PubMed
link]
|
